Our integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. We offer fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity, and developability. We enable our partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
As a profitable privately-held biotech company, we take a long-term view on value creation and make substantial investments in technology development, research, and our people. We proudly promote meritocracy and reward employees who are productive, use their resources wisely, and make meaningful contributions to the team. We offer individually tailored compensation packages comprised of competitive salary, equity, a 2:1 401(k) match, and comprehensive health care benefits.
Located in New Hampshire’s beautiful Upper Connecticut River Valley, Adimab is minutes from Dartmouth College, the Geisel School of Medicine, the Thayer School of Engineering, the Tuck School of Business, and the Dartmouth Hitchcock Medical Center. We are fortunate to be situated in an area that is renowned for its premier skiing, hiking, kayaking, and biking.
At Adimab, we leverage our proprietary yeast-based antibody discovery and optimization platform to provide the biopharmaceutical industry with human therapeutic antibodies of the highest quality. We partner with top-tier pharmaceutical companies, progressive academic institutions, and innovative biotechnology companies who share our passion for bringing best-in-class molecules to patients.
In collaboration with our partners, we have initiated over 150 therapeutic programs. Our partners include GSK, Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen, Novo Nordisk, Gilead, Kyowa Hakko Kirin, Pfizer, Sanofi, Celgene, Acceleron, Merrimack, Innovent, Oncothyreon, Surface Oncology, Potenza, Arsanis, Jounce, Five Prime Therapeutics, Alector, MD Anderson, Memorial Sloan Kettering, and more.
We are seeking an experienced scientist to join our Computational Biology group. The successful candidate will have prior experience in method and software development for structural modeling of proteins and protein:protein interactions. Candidates with experience in developing conformational sampling schemes or energy functions for protein design are especially encouraged to apply. Particular application areas for this role include antibody library design and developability assessment of therapeutic antibodies. The position will be located in Palo Alto, CA and and will closely interface with a team of scientists from Protein Analytics and Antibody Discovery located in Lebanon, NH.
• Develop, validate, and implement computational algorithms and software for three-dimensional structure modeling of antibodies and antibody:antigen complexes using Rosetta (or similar tools)
• Statistical data mining and modeling for sequence:structure and sequence:developability correlations
• Identify and implement novel approaches to protein modeling
• Interpret data and present work at both internal and external meetings
• Successfully collaborate with colleagues on the Technical Operations and Antibody Discovery teams
Needed upon hire
• Ph.D. in Biophysics, Biochemistry, or a related field
• 2-3 years of post-doctoral experience preferred
• Hands-on experience using Rosetta (preferred) or similar tools for protein structure modeling
• Advanced knowledge of object-oriented software development, preferably using C++ or other higher level languages
• In-depth knowledge of R for statistical analysis, data mining, and machine learning
• Strong track record of research accomplishments with three or more scientific journal publications in the area of macromolecular three-dimensional structure modeling
• Adaptable and productive in a fast-paced environment
• Ability to communicate effectively and openly with colleagues and supervisors
• Demonstrated independent thought and creativity in science